Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw unusually-strong trading volume on Monday . Approximately 68,240 shares traded hands during mid-day trading, a decline of 6% from the previous session’s volume of 72,456 shares.The stock last traded at $9.71 and had previously closed at $10.32.

Gyre Therapeutics Stock Down 3.4 %

The company’s fifty day moving average price is $11.31 and its 200-day moving average price is $12.35.

Insiders Place Their Bets

In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 30,054 shares of company stock valued at $342,277 over the last 90 days. Insiders own 19.52% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently added to or reduced their stakes in GYRE. FMR LLC purchased a new stake in shares of Gyre Therapeutics in the third quarter valued at approximately $47,000. Wells Fargo & Company MN lifted its holdings in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares during the period. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares during the period. Barclays PLC grew its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after buying an additional 1,389 shares during the period. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.